Activity from announced rounds
Deep Track Capital is a life-sciences investor identified by Draig Therapeutics and Superluminal Medicines.
Superluminal combines structural biology, protein dynamics, machine learning and experiments to discover small-molecule medicines. Draig develops neuropsychiatric treatments, while Triveni works on antibodies for immunological and inflammatory disorders. These company relationships give context to the recorded financings.
Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.
Draig Therapeutics develops neuropsychiatric medicines.
Develops novel antibody treatments for immunological and inflammatory disorders
Develops highly targeted, small molecule medicines for cancer and rare diseases
Drug-discovery company developing oral small-molecule treatments for obesity and metabolic disorders.